High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma

Figure 1

HE staining results of malignant mesothelioma biopsy (a) and reactive mesothelioma biopsy (b) (×200). HE staining results of malignant mesothelioma plasma cavity fluid specimens (c) and benign mesothelial tissue plasma cavity fluid specimens (d) (×200). SMO expression in mesothelioma biopsy specimens (e) and benign mesothelial tissue biopsy specimens (f) (×200). High expression of GLI1 in mesothelioma biopsy specimens (g) and low expression in benign mesothelial tissue (h) (×200). Expression of SMO antibodies in mesothelioma plasma membrane effusion specimens (i) and benign mesothelial tissue (j) (×200). GLI1-expressing antibody in plasma membrane cavity effusion specimens from mesothelioma (k) and benign mesothelial tissue (l) (×200).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)